B+
Bull case
25%
Probability
Target price
$7.10
+57.8% vs current
AUNA
AunaDNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$5.80
+28.9% vs current
B-
Bear case
25%
Probability
Target price
$3.90
-13.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-19
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+74.8
Score
AI commentary
Primary-source evidence confirms the earnings window, the preliminary KPI trend, and the FY26 guidance frame, but the memo remains low-conviction because the packet still lacks a fully digested earnings transcript or final filing details. No reliable immediate price-reaction or fresh analyst-revision signal is available in the evidence checked, so this is still a monitoring setup rather than a confirmed re-rating case.
RankAlpha Sentiment Codex - 2026-05-19
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-19catalystPost-print tape should hinge on whether the KPI momentum carries into the released 1Q26 numbersMedium impact
Auna’s April 17 KPI preview showed Peru surgery volumes rising to 26,428 from 24,990, Peru capacity utilization improving to 76.3% from 74.0%, OncoSalud memberships increasing to 1,439,781 from 1,364,710, and Colombia capacity utilization rising to 79.3% from 76.9%, while Mexico remained mixed with emergency treatments at 7,864 versus 8,053 [#6K-2026-04-17]. The May 19 earnings release is the near-term check on whether that operating mix translated into revenue and EBITDA quality.
2026-05-20event1Q26 earnings release and May 20 call provide the first full post-KPI financial readoutMedium impact
Auna’s first-quarter 2026 release and the May 20, 2026 8:00 AM ET conference call are the hard checkpoint for revenue, EBITDA, cash flow, and balance-sheet confirmation after the preliminary operating metrics [#IR-2026-05-19] [#6K-2026-04-17].
2026-12-31catalystFY26 guidance and Mexico stabilization remain the real rerating pathHigh impact
In the March 10 FY25 release, management said Mexico showed stabilization in late 4Q25 and the first two months of 2026 and guided to approximately 12% FXN revenue and Adjusted EBITDA growth for FY26, within a 10%-14% range, with broadly stable margins and capex around 4% of revenue [#PR-2026-03-10]. If that framework holds through the next few quarters, the stock can rerate; if Mexico softens again or margins slip, the thesis weakens quickly.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-19 • Updated nightlySource: Internal modelMethodology